The importance of informing on new therapies for cardiomyopathies

Medical scientific researchCardiomyopathies are a group of diseases that affect the heart muscle, causing impaired function of the heart muscle and even dangerous complications. Despite the efforts of medical research, to date there is no definitive cure. It is therefore crucial to disseminate precise scientific data on progress in the development of new therapies, which is one of the main activities in which AICARM has been engaged since its establishment.

Misinformation can fuel false hopes or even discourage patients from adhering to available treatments. On the contrary, communicating the results of studies, both positive and negative, in a transparent way allows you to maintain a realistic approach but at the same time encourages you to persevere in your research.

In addition to new therapies created with specific new generation drugs, research is also focusing on gene therapies that aim to correct the genetic mutations underlying some forms of cardiomyopathy. Recent preclinical studies have obtained encouraging results, but it is essential not to overestimate the timing of large-scale application.

In summary, correct and responsible scientific communication on research progress is of crucial importance, particularly in this historical period in which research innovations that were unimaginable until recently are appearing. Therefore, informing correctly on the one hand avoids generating false expectations in patients, while on the other it supports funding and efforts of the scientific community towards increasingly ambitious goals to defeat these serious pathologies.​​​​​​​​​​​​​​​​

For these reasons AICARM inaugurates a new column which will present the news and developments for the treatment of cardiomyopathies. We will present works that come from institutions and pharmaceutical companies, both Italian and foreign, always with authority and independence from the market, and in favor of patients with cardiomyopathy and their doctors.

Subscribe to AICARM NEWS
the AICARM APS Newsletter

Read our information on data processing Privacy Policy